Switching between treatments is an opportunity for patients with multiple sclerosis (MS) to ameliorate disease control or safety. The aim of this study was to investigate the impact of switching from fingolimod (FTY) or natalizumab (NTZ) to ocrelizumab (OCR) on disease activity.
Signoriello, E., Lus, G., Bonavita, S., Lanzillo, R., Saccà, F., Landi, D., et al. (2022). Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy. MULTIPLE SCLEROSIS, 28(1), 93-101 [10.1177/13524585211005657].
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy
Landi, Doriana;Marfia, Girolama Alessandra;
2022-01-01
Abstract
Switching between treatments is an opportunity for patients with multiple sclerosis (MS) to ameliorate disease control or safety. The aim of this study was to investigate the impact of switching from fingolimod (FTY) or natalizumab (NTZ) to ocrelizumab (OCR) on disease activity.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
signoriello2021.pdf
solo utenti autorizzati
Licenza:
Non specificato
Dimensione
552.51 kB
Formato
Adobe PDF
|
552.51 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
